Abvc Biopharma Q3 2026 Results: Turns Profitable, Net Income $1.15M
ABVC BioPharma reported accrued research and development expenses of $1,741,083 as of September 30, 2026, primarily for manufacturing and process development. The company noted potential increases in future accruals due to the planned resumption of ophthalmology and CNS clinical trials.
- Key figure
- Net income $1.15M